Page last updated: 2024-12-11
sabiporide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
sabiporide: a NHE-1 inhibitor and a cardioprotective agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9868115 |
| CHEMBL ID | 2105423 |
| SCHEMBL ID | 1286662 |
| MeSH ID | M0452989 |
Synonyms (19)
| Synonym |
|---|
| n-(diaminomethylidene)-4-[4-(1h-pyrrole-2-carbonyl)piperazin-1-yl]-3-(trifluoromethyl)benzamide |
| unii-u52apa00x7 |
| biib 722 |
| n-carbamimidoyl-4-(4-(1h-pyrrol-2-ylcarbonyl)piperazin-1-yl)-3-(trifluoromethyl)benzamide |
| sabiporide hcl |
| sabiporide [inn] |
| biib722 |
| 324758-66-9 |
| biib 722cl |
| u52apa00x7 , |
| biib-722 |
| sabiporide |
| CHEMBL2105423 |
| bdbm50396462 |
| 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine |
| SCHEMBL1286662 |
| 261505-80-0 |
| Q27290695 |
| DTXSID00870321 |
Research Excerpts
Treatment
Treatment with sabiporide significantly attenuated the increase in PAP by 38% and PVR by 67%, as well as significantly improved cardiac output by 51%. SabipOride treatment also improved mixed venous blood oxygen saturation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Sabiporide treatment also improved mixed venous blood oxygen saturation (55% in sabiporide group vs." | ( Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs. Abraham, WM; Kraut, JA; Wu, D, 2013) | 2.55 |
| "Treatment with sabiporide significantly attenuated the increase in PAP by 38% and PVR by 67%, as well as significantly improved cardiac output by 51%." | ( Sabiporide improves cardiovascular function, decreases the inflammatory response and reduces mortality in acute metabolic acidosis in pigs. Abraham, WM; Kraut, JA; Wu, D, 2013) | 2.17 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " In this study, we characterized the pharmacodynamic properties of new guanidine NHE1 inhibitors (cariporide, sabiporide, KR-32511, KR-32570, and KR-33028) to analyze their myocardial protective effects." | ( Pharmacodynamic characteristics and cardioprotective effects of new NHE1 inhibitors. Han, W; Jung, YS; Kim, J; Kim, KH; Kim, MY; Lee, BH; Lee, MG; Namkung, W; Yi, KY; Yoo, SE, 2007) | 0.55 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium/hydrogen exchanger 1 | Homo sapiens (human) | IC50 (µMol) | 0.0280 | 0.0050 | 0.5601 | 3.5000 | AID701661 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (40)
Molecular Functions (12)
Ceullar Components (16)
Bioassays (8)
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||